JP4126097B2 - Ｍｙｃｏｐｌａｓｍａ ａｒｔｈｒｉｔｉｄｉｓ由来アルギニンデイミナーゼ及びそれを含むポリマーコンジュゲート - Google Patents

Ｍｙｃｏｐｌａｓｍａ ａｒｔｈｒｉｔｉｄｉｓ由来アルギニンデイミナーゼ及びそれを含むポリマーコンジュゲート Download PDF

Info

Publication number
JP4126097B2
JP4126097B2 JP53303298A JP53303298A JP4126097B2 JP 4126097 B2 JP4126097 B2 JP 4126097B2 JP 53303298 A JP53303298 A JP 53303298A JP 53303298 A JP53303298 A JP 53303298A JP 4126097 B2 JP4126097 B2 JP 4126097B2
Authority
JP
Japan
Prior art keywords
arginine deiminase
adi
nucleic acid
seq
antigenic polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP53303298A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001512965A5 (https=
JP2001512965A (ja
Inventor
フィルプラ，デビッド，レイ．
ワン，マオリン
Original Assignee
エンゾン，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エンゾン，インコーポレーテッド filed Critical エンゾン，インコーポレーテッド
Publication of JP2001512965A publication Critical patent/JP2001512965A/ja
Publication of JP2001512965A5 publication Critical patent/JP2001512965A5/ja
Application granted granted Critical
Publication of JP4126097B2 publication Critical patent/JP4126097B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/10—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a carbohydrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
JP53303298A 1997-01-31 1998-01-27 Ｍｙｃｏｐｌａｓｍａ ａｒｔｈｒｉｔｉｄｉｓ由来アルギニンデイミナーゼ及びそれを含むポリマーコンジュゲート Expired - Fee Related JP4126097B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/792,283 1997-01-31
US08/792,283 US5804183A (en) 1997-01-31 1997-01-31 Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same
PCT/US1998/001635 WO1998033519A1 (en) 1997-01-31 1998-01-27 Arginine deiminase derived from mycoplasma arthritidis and polymer conjugates containing the same

Publications (3)

Publication Number Publication Date
JP2001512965A JP2001512965A (ja) 2001-08-28
JP2001512965A5 JP2001512965A5 (https=) 2005-07-14
JP4126097B2 true JP4126097B2 (ja) 2008-07-30

Family

ID=25156365

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53303298A Expired - Fee Related JP4126097B2 (ja) 1997-01-31 1998-01-27 Ｍｙｃｏｐｌａｓｍａ ａｒｔｈｒｉｔｉｄｉｓ由来アルギニンデイミナーゼ及びそれを含むポリマーコンジュゲート

Country Status (9)

Country Link
US (3) US5804183A (https=)
EP (1) EP1011717B1 (https=)
JP (1) JP4126097B2 (https=)
AT (1) ATE314086T1 (https=)
AU (1) AU6047598A (https=)
DE (1) DE69832993T2 (https=)
DK (1) DK1011717T3 (https=)
ES (1) ES2255147T3 (https=)
WO (1) WO1998033519A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6183738B1 (en) * 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US6635462B1 (en) * 1997-05-12 2003-10-21 Phoenix Pharmacologies, Inc. Mutated form of arginine deiminase
WO2002044360A2 (en) * 2000-11-28 2002-06-06 Phoenix Pharmacologics, Inc. Modified arginine deiminase
US6645739B2 (en) * 2001-07-26 2003-11-11 Phoenix Pharmacologies, Inc. Yeast expression systems, methods of producing polypeptides in yeast, and compositions relating to same
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
AU2003282883B2 (en) * 2002-11-18 2008-12-04 Polaris Group Methods for inhibiting viral replication in vivo
FR2884717B1 (fr) * 2005-04-25 2009-07-03 Erytech Pharma Soc Par Actions Erythrocytes renfermant de l'arginine deiminase
EP2444499A3 (en) 2006-05-02 2012-05-09 Allozyne, Inc. Amino acid substituted molecules
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
FR2919804B1 (fr) 2007-08-08 2010-08-27 Erytech Pharma Composition et vaccin therapeutique anti-tumoral
CA2707840A1 (en) * 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
JP2009044997A (ja) * 2007-08-20 2009-03-05 Sony Corp ビリルビンオキシダーゼ（ｂｏｄ）の被覆方法
EP2295560A1 (en) 2009-09-14 2011-03-16 RWTH Aachen University Directed evolution of arginine deiminase for increased activity at physiological pH
US9255262B2 (en) * 2013-03-06 2016-02-09 Vision Global Holdings Ltd. Albumin-binding arginine deminase and the use thereof
USRE48805E1 (en) 2013-03-06 2021-11-02 Vision Global Holdings Ltd. Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein
EP3744341A1 (en) 2013-03-15 2020-12-02 TDW Group Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment
KR102523031B1 (ko) * 2014-03-18 2023-04-19 티디더블유 그룹 조작된 키메라성 페길화된 adi 및 사용 방법
JP6782230B2 (ja) 2014-09-16 2020-11-11 ティーディーダブリュー グループ 癌治療のためのａｄｉ−ｐｅｇ２０抗体に対する交差反応性が低減したアルギニンデイミナーゼ
EP3344575B1 (en) 2015-09-04 2020-04-15 SQZ Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
JP7602702B2 (ja) 2016-05-03 2024-12-19 ステムセル テクノロジーズ カナダ インコーポレーテッド 寛容性を誘導するための生体分子の細胞内送達
TWI847958B (zh) 2016-07-05 2024-07-11 英屬開曼群島商北極星藥業集團股份有限公司 用精胺酸耗盡劑進行之組合癌症免疫療法
TWI784982B (zh) 2016-11-02 2022-12-01 開曼群島商北極星藥業集團股份有限公司 聚乙二醇化精胺酸脫亞胺酶之調配物
CA3042442C (en) 2016-11-14 2024-01-02 Hangzhou Dac Biotech Co., Ltd Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses of such conjugates with the linkers
TWI911136B (zh) 2017-03-29 2026-01-11 開曼群島商北極星藥業集團股份有限公司 蛋白質結合物
EP3449935A1 (en) 2017-08-31 2019-03-06 Erytech Pharma Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency
WO2019042628A1 (en) 2017-08-31 2019-03-07 Erytech Pharma ARGININE DEIMINASE ENCAPSULATED WITHIN ERYTHROCYTES AND THEIR USE IN THE TREATMENT OF CANCER AND ARGINASE-1 DEFICIENCY
MX2022001425A (es) * 2019-08-01 2022-05-02 Univ North Carolina Chapel Hill Composiciones y metodos para la union de anticuerpos y la inhibicion de anticuerpos neutralizantes.
EP3954393A1 (en) 2020-08-13 2022-02-16 Bioasis Technologies Inc. Combination therapies for delivery across the blood brain barrier
EP4288445A1 (en) * 2021-02-03 2023-12-13 The University of North Carolina at Chapel Hill Protein m analogs and fusion proteins and their use for inhibiting antibody function
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPH0253490A (ja) * 1988-08-16 1990-02-22 Agency Of Ind Science & Technol アルギニン・デイミナーゼ遺伝子
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
JP2900279B2 (ja) * 1989-08-02 1999-06-02 株式会社ジャパンエナジー 新規なアルギニンデイミナーゼ、その製造法及び該酵素を有効成分とする制癌剤
JP3209338B2 (ja) * 1990-09-10 2001-09-17 株式会社ジャパンエナジー ポリエチレングリコール修飾アルギニンデイミナーゼおよびその製造法
US5372942A (en) * 1992-02-10 1994-12-13 Coriell Institute For Medical Research Protease K resistant arginine deiminase, its method of preparation and its use as an anti-neoplastic agent
US5349001A (en) * 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same

Also Published As

Publication number Publication date
US6132713A (en) 2000-10-17
EP1011717A4 (en) 2003-02-19
ES2255147T3 (es) 2006-06-16
US5916793A (en) 1999-06-29
ATE314086T1 (de) 2006-01-15
US5804183A (en) 1998-09-08
WO1998033519A1 (en) 1998-08-06
DE69832993D1 (de) 2006-02-02
DE69832993T2 (de) 2006-09-07
JP2001512965A (ja) 2001-08-28
AU6047598A (en) 1998-08-25
EP1011717A1 (en) 2000-06-28
DK1011717T3 (da) 2006-05-15
EP1011717B1 (en) 2005-12-28

Similar Documents

Publication Publication Date Title
JP4126097B2 (ja) Ｍｙｃｏｐｌａｓｍａ ａｒｔｈｒｉｔｉｄｉｓ由来アルギニンデイミナーゼ及びそれを含むポリマーコンジュゲート
US20210023230A1 (en) Conjugates of an il-2 moiety and a polymer
Rodríguez‐Martínez et al. Stabilization of α‐chymotrypsin upon PEGylation correlates with reduced structural dynamics
US20060239960A1 (en) Polymer-based compositions and conjugates of antimicrobial agents
US11021690B2 (en) Mutant-type uricase, PEG modified mutant-type uricase, and application thereof
ES2569940T3 (es) Adenosina desaminasa recombinante estable
KR101408062B1 (ko) Ｌ-아스파라기나아제 ⅱ 제조를 위한 재조합 숙주
JPH10510980A (ja) 巨核球の成長と分化を刺激する組成物とその方法
US20180207286A1 (en) Conjugates of a cholinesterase moiety and a polymer
CA3153029A1 (en) Improved uricase and method for treating hyperuricemia using same
JP2003533186A (ja) アルギニンデイミナーゼの新規突然変異体
JP2010500963A (ja) 安定化タンパク質
CN103923209B (zh) 一种Lambda干扰素突变体及聚乙二醇衍生物
CN111050784A (zh) 截短的豚鼠l-天冬酰胺酶变体及其使用方法
TWI465460B (zh) 用於治療病毒感染及癌症之新穎醫藥組合物
CN105085658B (zh) 一种白细胞介素29突变体及聚乙二醇衍生物
CN1536079A (zh) 修饰的精氨酸脱亚氨酶
CN117645661A (zh) 一种聚乙二醇修饰的il-21衍生物及其应用
WO2006015512A1 (en) A modified arginine deiminase
AU782635B2 (en) Interferon gamma conjugates
HK40126475A (zh) 白介素-2多肽偶联物及其使用方法
HK40021199B (zh) 白介素-2多肽偶联物及其用途
HK40074343B (zh) 白介素-2多肽偶联物及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041027

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070522

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070809

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080415

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080512

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110516

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees